Technical Analysis with a Quantitative Edge

SIGN UP  |  LOGIN

HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

Merrimack Pharmaceuticals, Inc. (MACK)
Equity - Health Care - Major Pharmaceuticals

 

As of 2017-10-19

Add to My Portfolio
Close13.12Open13.15
Prev Close13.26Daily Chg-0.14 (-1.06%)
High13.34Volume105,464
Low12.9552-Week High/Low15.09 / 1.16
Dividend Yield0%Curr P/E0.41
Curr Year EPS Est33.49Fwd P/E0.39
P/B1.65Short Ratio18.07
P/S1.22PEG Ratio0.07
Latest QuantForecast
As Of
Customize QuantForecast   View Commentary & Pattern   Save To My Forecasts     Share

 
 
 

SUPPORT
Lower Boll Band: 12.70 50SMA: 9.45 100SMA: 5.40
RESISTANCE
9EMA: 13.50 20SMA: 14.08 Upper Boll Band: 15.46
COMMENTARY
Short-term pullback but still in a long-term uptrend . Near-term technicals are oversold with MACD below zero 18 Days in a row and MACD near historical low. Forecast points to higher price but with choppy action
TECHNICAL PATTERN

TYPEDESCRIPTION (?)CRITERIA (?)
Oversold Condition MACD is below zero 18 Days in a row, historically only happened 9.48% of the time MACD Above/Below Zero Streak = -18
FORECAST STATISTICS
TIMEFRAME 2-DAY 5-DAY 10-DAY 20-DAY
Average -0.32% -0.02% -1.37% +12.19%
Best +5.45% +23.73% +21.12% +51.47%
Worst -8.96% -16.18% -30.08% -31.96%
% Positive 50% 50% 50% 64%
Outlook NEUTRAL NEUTRAL NEUTRAL BULLISH
HISTORICAL MATCHES (?)
MATCH DATE 2-DAY 5-DAY 10-DAY 20-DAY
2017-10-19 0% 0% 0% 0%
2017-06-15 +0.85% +23.73% +9.32% +15.25%
2016-12-21 -0.68% -6.62% -17.81% -31.96%
2016-09-01 +1.74% -3.05% +2.18% +38.34%
2016-07-07 -1.42% -8.90% -4.63% +5.34%
2016-04-28 -0.14% -9.05% -14.81% -10.29%
2015-08-03 +5.45% -7.30% +4.96% -1.85%
2015-02-05 -0.11% +8.03% +21.12% +36.19%
2014-06-26 +0.41% +2.75% -6.34% -21.35%
2014-04-15 +2.49% +11.56% -0.45% +51.47%
2014-02-12 +1.25% +1.66% +5.20% +17.26%
# Matches 14 Next
TRADE SIGNALS ?
POSITIONENTRY DATEENTRY PRICETARGET PRICE (?)STOP PRICE (?)CURRENT PNL %
Premium Members Only

Upgrade Now & Subscribe to Daily Trade Signals

CLOSED TRADES
POSITIONENTRY DATEENTRY PRICEEXIT DATE EXIT PRICEREALIZED PNL %
Short 2016-03-21 8.30 2016-04-28 7.29 +12.17%
Long 2014-04-29 4.49 2014-05-08 6.38 +42.09%
Related Stocks
SYMBOL NAME Close VOLUME CHG WTD MTD YTD QUANTFORECAST(?)
2-DAY 5-DAY 10-DAY 20-DAY
JNJ Johnson & Johnson 142.06 6,864,255 +1.37 (+0.97%) +5.54 (+4.06%) +12.09 (+9.30%) +27.60 (+24.11%)
PFE Pfizer, Inc. 36.25 15,234,859 +0.42 (+1.17%) -0.10 (-0.28%) +0.58 (+1.63%) +4.40 (+13.83%)
MRK Merck & Company, Inc. 63.78 6,474,636 +0.28 (+0.44%) +0.38 (+0.60%) -0.24 (-0.37%) +5.34 (+9.13%)
SNY Sanofi 49.99 359,769 +0.45 (+0.91%) +0.49 (+0.99%) +0.18 (+0.36%) +9.55 (+23.62%)
ABBV AbbVie Inc. 96.61 8,459,386 +0.65 (+0.68%) +5.91 (+6.52%) +7.75 (+8.72%) +35.25 (+57.45%)
>>> See More Related Stocks
LATEST BUZZ
@DrCruler
Posted 2017-10-20T12:12:10Z
$MACK let's release the dogs to make those cats flee!!!
@Milkbone
Posted 2017-10-20T04:21:32Z
$MACK Merrimack Pharmaceuticals is ranked #48 in WATCHERS for healthcare stocks. http://www.stockmarket-health.com
@jathman
Posted 2017-10-19T23:49:45Z
$MACK @Quagglerock i guess that 720% day is still ahead of us
@TheBee
Posted 2017-10-19T19:11:38Z
$MACK I've already held this long.
@kingscats
Posted 2017-10-19T18:51:26Z
$MACK 2018 ain't gonna be pretty at least till 4Q. Just sayin
@poostinky
Posted 2017-10-19T18:31:20Z
$MACK I dream of this time 2018
@DrCruler
Posted 2017-10-19T16:20:28Z
$MACK o don't understand the game played by the mgt and their communication plan. Why don't they release PR about milestones achievements?
@scistats
Posted 2017-10-19T13:25:03Z
$MACK Also,SilverCreek once/still? held in part by CrockerVentures but being progress by Merrimack,if divested, a conflict of interest?
@scistats
Posted 2017-10-19T13:20:27Z
$MACK Stockholders need more insight/color to know whether MACK's preclinical candidates are a house of cards or viable based on data.
@scistats
Posted 2017-10-19T13:15:23Z
$MACK In total Merrimack stockholders have 7 preclinical candidates. We really need to know the viability of our preclinical business.
@scistats
Posted 2017-10-19T13:09:02Z
$MACK In cell model for heart, SC777 (control) did not display a potency shift but SC776 had a potency shift of 57-fold
@jathman
Posted 2017-10-19T13:01:42Z
$MACK Quaggle, you sober yet?
@Quagglerock
Posted 2017-10-18T21:44:30Z
$MACK TBRA 2.0. Its coming.
@jathman
Posted 2017-10-18T15:17:07Z
$MACK POS
@Quagglerock
Posted 2017-10-18T14:58:08Z
$MACK C'mon @jathman! Turn this thing around with your daily POS post.
@wallstreetmomos
Posted 2017-10-18T14:48:58Z
Put $MACK in your radar as a short below $12.60. Would risk $0.80 with a stop loss @$13.40. #Swingtrader #Daytrader #Tips
@shockvshock1
Posted 2017-10-18T13:46:43Z
$MACK WOW! check out CREE...
@SimpleFarmer
Posted 2017-10-18T09:31:35Z
$MACK i just cant miss out gents. scaling back in here, added a 250 share teaser
@EstimizeAlerts
Posted 2017-10-18T05:23:27Z
$MACK estimates distribution - here’s what 5 Estimize analysts are expecting $MACK to report for Q3 [Reporting 11/09 BMO] http://www.estimize.com/intro/mack?utm_content=MACK&utm_medium=eps_update&utm_source=stocktwits#chart=historical
@DosGatos
Posted 2017-10-17T23:46:19Z
@Decentralized $SGYP has one huge advantage over $MACK - Crocker is not on the BOD!
MACK LATEST NEWS
Health Care Sector Update for 10/13/2017: MACK
Posted Fri, 13 Oct 2017 13:31:50 Z
Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 1 PFE 0 1 ABT flatABT flat MRK flatMRK flat AMGN flatAMGN flat Health care shares were mainly unchanged in pre market trade Friday Health care shares were mainly unchanged in pre market trade Friday In health... >>> Read More
AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back
Posted Wed, 11 Oct 2017 21:48:00 Z
AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back... >>> Read More
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
Posted Thu, 10 Aug 2017 16:39:49 Z
Merrimack Pharmaceuticals Inc MACK reported a loss of 22 cents per share in the second quarter of 2017 wider than the Zacks Consensus Estimate of a loss of 14 cents The company had reported a loss of 41 cents in the year ago quarter Merrimack completed the sale of Onivyde and a... >>> Read More
Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss
Posted Wed, 09 Aug 2017 13:39:18 Z
Cambridge MA based Merrimack Pharmaceuticals Inc MACK is a biopharmaceutical company focused on the discovery development and commercialization of innovative therapies in combination with companion diagnostics for the treatment of cancer Merrimack completed the sale of its only... >>> Read More
What's in the Cards for Merrimack (MACK) in Q2 Earnings?
Posted Fri, 28 Jul 2017 16:58:43 Z
Merrimack Pharmaceuticals Inc MACK is expected to report second quarter 2017 results around Aug 3 Last quarter Merrimack missed bottom line expectations by 214 29 Merrimack s share price has decreased 67 4 year to date against the industry s gain of 10 Let s see how things... >>> Read More

WINGCHARTS.COM    HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

 



Follow Us on StockTwits
Partners / Affiliates

Copyright © 2017 WingCapital Co., Ltd. All Rights Reserved.

Disclaimer: Past results are not necessarily indicative of future performance. This website is for educational purposes only. No content published in this website, services and products constitutes a recommendation that any particular investment, security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Practical use of the content, forecasts, charts and services provided in this website are at your own risk and WingCapital Co., Ltd., WingCharts.com, its partners, representatives and employees assume no responsibility or liability for any use of the website. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Trade signals shown are hypothetical and do not represent actual trades. Actual results may differ. Views, forecasts and commentaries expressed in this website are WingCapital Co., Ltd.'s own opinions, and are not guarantees of future performance, and are subject to change over time.

WingCharts.com and WingCapital Co., Ltd. are not registered investment advisor or a broker dealer and do not give individualized market advice. The information on this website is for illustration purposes only and should not be considered as a solicitation of an offer on the purchase or sale of any securities. Trading in the securities markets involves substantial risk and should not be undertaken without due diligence and serious independent study. WingCapital Co., Ltd. recommends consulting a licensed professional broker regarding your personal investments. Without limitation, WingCapital Co., Ltd. shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscribers inability to use or any delay in accessing the WingCharts.com website or any other source of material provided by WingCharts.com and WingCapital Co., Ltd.; (3) any absence or error of material on WingCharts.com website or presentation; (4) WingCapital Co., Ltd. failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material.

ALL INFORMATION AND MATERIALS ARE PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.